Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w

cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w

trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w

pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w

docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w

docetaxel (T) 75 mg/m\^2, i.v., d1, q3w

carboplatin (Cb) AUC 6, i.v., d1, q3w

trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w

pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w